These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30121825)

  • 21. [EFFECT OF TADALAFIL THAT WAS ADDITIONALLY ADMINISTERED TO PATIENTS RECEIVING AN ALPHA1-BLOCKER IN JAPANESE MEN WITH LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA].
    Hayashi K; Fukagai T; Koshikiya A; Igarashi A; Morita M; Sasaki H; Ishikawa K
    Nihon Hinyokika Gakkai Zasshi; 2016; 107(1):28-33. PubMed ID: 28132988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial.
    Sebastianelli A; Spatafora P; Frizzi J; Saleh O; De Nunzio C; Tubaro A; Vignozzi L; Maggi M; Serni S; McVary KT; Kaplan SA; Gravas S; Chapple C; Gacci M
    Eur Urol Focus; 2021 Mar; 7(2):432-439. PubMed ID: 31606473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
    AbdelRazek M; Abolyosr A; Mhammed O; Fathi A; Talaat M; Hassan A
    World J Urol; 2022 Aug; 40(8):2063-2070. PubMed ID: 35773357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?
    Cornu JN; Grise P
    Curr Opin Urol; 2016 Jan; 26(1):17-21. PubMed ID: 26574877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
    Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
    Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of resistive index of the prostate and bladder sonomorphologic parameters as replacements for urodynamics to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Garg G; Sankhwar SN; Goel A; Pandey S; Sharma D; Parihar A
    Low Urin Tract Symptoms; 2019 May; 11(3):163-168. PubMed ID: 30793849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
    Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
    BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cluster analysis of men undergoing surgery for BPH/LUTS reveals prominent roles of both bladder outlet obstruction and diminished bladder contractility.
    Schneider AJ; Grimes M; Lyon W; Kemper A; Wang S; Bushman W
    PLoS One; 2021; 16(5):e0251721. PubMed ID: 34029333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology.
    Villa L; Capogrosso P; Capitanio U; Martini A; Briganti A; Salonia A; Montorsi F
    Adv Ther; 2019 Jan; 36(1):1-18. PubMed ID: 30523608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    McVary KT; Peterson A; Donatucci CF; Baygani S; Henneges C; Clouth J; Wong D; Oelke M
    J Urol; 2016 Sep; 196(3):824-30. PubMed ID: 27105760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-treatment serum testosterone level can be a useful factor to predict the improvement in bladder outlet obstruction by tadalafil for male patients with lower urinary tract symptoms induced by benign prostatic obstruction.
    Matsukawa Y; Kanada Y; Takai S; Inoue S; Majima T; Funahashi Y; Kato M; Yamamoto T; Gotoh M
    Aging Male; 2020 Dec; 23(5):641-647. PubMed ID: 30651033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.